725,000 Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC) Acquired by Oddo BHF Asset Management Sas

Oddo BHF Asset Management Sas bought a new position in Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 725,000 shares of the biopharmaceutical company's stock, valued at approximately $3,763,000. Oddo BHF Asset Management Sas owned about 0.69% of Revance Therapeutics at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in RVNC. Certuity LLC purchased a new position in Revance Therapeutics during the 2nd quarter worth $26,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Revance Therapeutics in the 2nd quarter valued at $33,000. Hsbc Holdings PLC acquired a new stake in shares of Revance Therapeutics during the second quarter worth about $38,000. Nisa Investment Advisors LLC boosted its position in Revance Therapeutics by 2,167.5% in the second quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 18,077 shares during the last quarter. Finally, FORA Capital LLC acquired a new position in Revance Therapeutics in the 3rd quarter worth approximately $54,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Revance Therapeutics Trading Down 0.3 %

RVNC stock traded down $0.01 during mid-day trading on Friday, reaching $3.08. The company's stock had a trading volume of 3,570,442 shares, compared to its average volume of 2,809,723. Revance Therapeutics, Inc. has a fifty-two week low of $2.30 and a fifty-two week high of $9.74. The stock has a market cap of $323.09 million, a PE ratio of -1.60 and a beta of 0.81. The company's 50 day moving average is $4.60 and its two-hundred day moving average is $4.46.

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). The firm had revenue of $59.88 million for the quarter, compared to analyst estimates of $67.73 million. On average, analysts forecast that Revance Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on RVNC shares. StockNews.com initiated coverage on shares of Revance Therapeutics in a report on Thursday. They set a "hold" rating for the company. HC Wainwright reaffirmed a "neutral" rating and set a $6.60 target price on shares of Revance Therapeutics in a report on Friday, November 8th. Needham & Company LLC reissued a "hold" rating on shares of Revance Therapeutics in a report on Friday, November 8th. Barclays reaffirmed an "equal weight" rating and set a $7.00 price objective (down previously from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. Finally, Mizuho decreased their target price on shares of Revance Therapeutics from $6.66 to $3.10 and set a "neutral" rating for the company in a research note on Tuesday. Nine research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $8.96.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.